Document:

Exhibit
10.5

 

AGREEMENT
TO TERMINATE 

STOCK
PURCHASE AGREEMENT

 

Effective
as of February 28, 2022 (the “Effective Date”), Heng Fai Ambrose Chan (the “Buyer”), and Alset EHome International
Inc. (the “Seller”) enter into and agree as provided in this Agreement to Terminate Stock Purchase Agreement (the “Termination
Agreement”).

 

RECITALS:

 

		A.	Buyer
                                            and Seller are parties to a Stock Purchase Agreement dated into January 24, 2022 (the “Purchase
                                            Agreement”).

 

		B.	The
                                            parties now desire to terminate the Purchase Agreement as provided in this Termination Agreement.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Buyer and Seller agree
as follows:

 

		1.	Termination.
                                            The Purchase Agreement and each of its terms and provisions will in all respects terminate,
                                            be canceled and have no further force or effect from and after the Effective Date.

 

		2.	No
                                            Further Obligations. From and after the Effective Date, no party to the Purchase
                                            Agreement will have any further obligation under, as a result of or in connection with the
                                            Purchase Agreement, and each party to this Termination Agreement releases each of the other
                                            parties from any such obligation.

 

		3.	Miscellaneous.
                                            This Termination Agreement (i) will be binding upon the parties and their respective
                                            successors and assigns; (ii) may not be modified or amended except by a written instrument
                                            signed by each party against whom enforcement of the modification or amendment is sought;
                                            (iii) may be executed in any number of counterparts, and by any party on a separate counterpart,
                                            all of which together will constitute one and the same instrument. A signed counterpart of
                                            this Agreement faxed, or scanned and emailed, by a party to another party will constitute
                                            delivery by the sending party to the recipient party, may be treated by the recipient party
                                            as an original, and will be admissible as evidence of such signed and delivered counterpart.

 

Executed
as of the date first written above.

 

	 	 	 	Alset
    EHome International, Inc. 
	 	 	 	 
	By:	/s/
    Heng Fai Ambrose Chan	 	By:	/s/
    Alan Lui
	 	Heng
    Fai Ambrose Chan	 	 	Alan
    Lui 
	 	 	 	 	Co-Chief
    Financial OfficerExhibit
10.6

 

AGREEMENT
TO TERMINATE 

STOCK
PURCHASE AGREEMENT

 

Effective
as of February 28, 2022 (the “Effective Date”), DSS, Inc. (the “Buyer”), and Alset EHome International Inc. (the
“Seller”) enter into and agree as provided in this Agreement to Terminate Stock Purchase Agreement (the “Termination
Agreement”).

 

RECITALS:

 

	 	A.	Buyer
    and Seller are parties to a Stock Purchase Agreement dated into January 18, 2022 wherein the Buyer was to purchase 877,248,065 of
    the common shares of Alset International Limited owned by Seller (the “Purchase Agreement”).
	 	 	 
	 	B.	The
    parties now desire to terminate the Purchase Agreement as provided in this Termination Agreement.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Buyer and Seller agree
as follows:

 

	 	1.	Termination.
    The Purchase Agreement and each of its terms and provisions will in all respects terminate, be canceled and have no further force
    or effect from and after the Effective Date.
	 	 	 
	 	2.	No
    Further Obligations. From and after the Effective Date, no party to the Purchase Agreement will have any further obligation
    under, as a result of or in connection with the Purchase Agreement, and each party to this Termination Agreement releases each of
    the other parties from any such obligation.
	 	 	 
	 	3.	Miscellaneous.
    This Termination Agreement (i) will be binding upon the parties and their respective successors and assigns; (ii) may not be
    modified or amended except by a written instrument signed by each party against whom enforcement of the modification or amendment
    is sought; (iii) may be executed in any number of counterparts, and by any party on a separate counterpart, all of which together
    will constitute one and the same instrument. A signed counterpart of this Agreement faxed, or scanned and emailed, by a party to
    another party will constitute delivery by the sending party to the recipient party, may be treated by the recipient party as an original,
    and will be admissible as evidence of such signed and delivered counterpart.

 

Executed
as of the date first written above.

 

	DSS,
    Inc.	 	Alset
    EHome International Inc. 
	 	 	 	 	 
	By:	 /s/
    Frank D. Heuszel	 	By:	 /s/
    Alan Lui
	 	Frank
    D. Heuszel	 	 	Alan
    Lui 
	 	Chief
    Executive Officer	 	 	Co-Chief
    Financial Officerxene-ex1030_191.htm

 

CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL.

Exhibit 10.30

February 25, 2022

 

Neurocrine Biosciences, Inc.

12780 El Camino Real

San Diego, California 

92130, U.S.

Attention: Kyle Gano

Dear Kyle,

Re: License and Collaboration Agreement between Xenon Pharmaceuticals Inc. (“Xenon”) and Neurocrine Biosciences, Inc. (“Neurocrine”) made as of December 2, 2019, as previously amended (the “Agreement”)

 

Further to our recent discussions and in accordance with Section 14.8 of the Agreement, and in consideration of the premises and mutual covenants contained herein, Xenon and Neurocrine agree as follows:

 

	
1.
	
LETTER AMENDMENT #2

 

Except as specifically defined below, capitalized terms used in this Letter Amendment #2 shall have the same meaning as ascribed to such terms in the Agreement. 

 

	
2.
	
DEFINITION

 

	
2.1
	
Section 1.81 “Pain Field” of the Agreement shall be replaced with the following definition:

“Pain Field means treating the following diseases with a compound whose primary mechanism is NaV1.6 modulation and it binds to and modulates NaV1.7 with an IC50 of 1microM or less: pain indications and pain associated with other diseases or conditions.

 

	
3.
	
RIGHTS IN THE PAIN FIELD

 

	
3.1
	
Section 2.1 (c) of the Agreement shall be amended and restated as follows:

“(c) Restriction. Neurocrine shall not, directly or indirectly, Develop, seek Regulatory Approval for, market or promote any Excluded Compound.”

 

 

 

 

	
3.2
	
Section 8.8 of the Agreement shall be amended and restated as follows: 

“Third Party Payment Obligations. Subject to Section 8.7(e)(ii) and Section 9.6, each Party shall be responsible for the payment of royalty, milestone and other payments due to Third Parties under any agreements between such Party (or its Affiliates) and Third Parties on account of Neurocrine’s and its Affiliates’ and sublicensees’ Development, manufacture and Commercialization of Products in the Field in the Territory. Without limiting the foregoing, Xenon shall be solely responsible for all payments due under the Genentech License; provided, however, that Neurocrine will, in addition to the applicable royalty rate, pay to Xenon [***] of all payments due under the Genentech License on any Net Sales of Products containing an Early Compound for which the package insert includes at least one category of pain covered under the definition of the Pain Field. In the event that Xenon has failed to make any payment on account of Neurocrine’s or its Affiliate’s or sublicensee’s sale of any Product when due under the Genentech License, and has failed to cure such non-payment within the applicable cure period under the Genentech License, Xenon will provide notice to Neurocrine at least [***] days prior the end of the applicable cure period and Neurocrine shall have the right, but no obligation, to pay any such royalties directly to Genentech and to deduct any such royalties paid to Genentech against any payments to Xenon under this Agreement.” 

 

	
4.
	
GENERAL

 

	
4.1
	
This Letter Amendment #2 amends the terms of the Agreement and is deemed incorporated into, and governed by all other terms of, the Agreement. The Agreement shall, together with this Letter Amendment #2, be read and construed as a single instrument.

 

	
4.2
	
In the event of a conflict between the terms of this Letter Amendment #2 and the terms of the Agreement, to the extent that the Agreement is explicitly amended by this Letter Amendment #2, the terms of this Letter Amendment #2 shall prevail.

 

	
4.3
	
Except as specifically provided above in this Letter Amendment #2, the Agreement remains in full force and effect.

 

	
4.4
	
This Letter Amendment #2 may be signed in any number of counterparts, including electronic scan copies thereof delivered by electronic mail, each of which shall be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.

 

 

 

 

 

By the signatures below, the Parties have caused this Letter Amendment #2 to be executed by their respective duly authorized officers to be effective as of the date of this Amendment #2.

 

Sincerely,

 

Xenon Pharmaceuticals Inc.

 

			
	
By: /s/ Ian Mortimer____________________
	
 
	
By: /s/ Robin Sherrington_________________

	
Ian Mortimer

President & CEO
	
 
	
Robin Sherrington

EVP, Business and Corporate Development

 

 

Neurocrine Biosciences, Inc.

 

	
	
By: /s/ Kyle Gano________________________

	
Name: Kyle Gano

Title: Chief Business Development Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]